NCI Director Broder, Going On 3rd Year, Examines Issues Of Funding, Priorities, For Institute’s Future
In Brief: Tipping Resigns Forom ACS; Vaughan Joins UAB BMT Program; PCI Recruits Ball, Finn, Mirro
‘Be Careful We’re Not Fighting Old Battles’ On Study Section Issue
‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’
“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s
Centers Program Needs ‘Innovative Additions’ Such as SPORE Grants
Broder Not Satisfied With Mortality STATS On Three Major Cancers
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup
